Ally Financial Inc. Buys New Shares in Solventum Corporation $SOLV

Ally Financial Inc. purchased a new stake in shares of Solventum Corporation (NYSE:SOLV - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 12,500 shares of the company's stock, valued at approximately $964,000.

Other hedge funds have also bought and sold shares of the company. Independent Franchise Partners LLP raised its stake in Solventum by 19.0% during the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company's stock worth $1,216,785,000 after acquiring an additional 2,456,451 shares during the period. State Street Corp increased its stake in shares of Solventum by 2.0% in the fourth quarter. State Street Corp now owns 6,344,761 shares of the company's stock worth $502,759,000 after purchasing an additional 124,490 shares in the last quarter. Davis Selected Advisers increased its stake in shares of Solventum by 12.7% in the fourth quarter. Davis Selected Advisers now owns 6,220,072 shares of the company's stock worth $492,880,000 after purchasing an additional 702,461 shares in the last quarter. Boston Partners raised its position in shares of Solventum by 26.1% during the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company's stock valued at $338,006,000 after purchasing an additional 959,543 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Solventum by 20.0% during the 4th quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company's stock valued at $362,375,000 after purchasing an additional 763,308 shares during the period.

Solventum Stock Up 0.1%

SOLV opened at $89.64 on Monday. The company has a market capitalization of $15.26 billion, a PE ratio of 10.96, a price-to-earnings-growth ratio of 1.15 and a beta of 0.60. The firm has a 50-day simple moving average of $80.91 and a two-hundred day simple moving average of $75.03. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $90.00.

Solventum (NYSE:SOLV - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.64. The firm had revenue of $2.21 billion for the quarter, compared to analysts' expectations of $2.15 billion. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The business's revenue was up 2.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.69 earnings per share. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Analysts forecast that Solventum Corporation will post 7.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SOLV has been the topic of a number of recent analyst reports. BTIG Research raised their price target on Solventum from $91.00 to $95.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Wedbush upped their price objective on Solventum from $94.00 to $101.00 and gave the stock an "outperform" rating in a research note on Thursday, August 6th. BMO Capital Markets started coverage on Solventum in a research report on Wednesday, July 8th. They set a "market perform" rating and a $81.00 target price for the company. Piper Sandler lifted their target price on Solventum from $92.00 to $105.00 and gave the company an "overweight" rating in a research note on Thursday, August 6th. Finally, Stifel Nicolaus boosted their price target on Solventum from $90.00 to $100.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $91.64.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source